Details

Autor(en) / Beteiligte

• O'Brien, Meagan P
• Forleo-Neto, Eduardo
• Sarkar, Neena
• Isa, Flonza
• Hou, Peijie
• Chan, Kuo-Chen
• Musser, Bret J
• Bar, Katharine J
• Barnabas, Ruanne V
• Barouch, Dan H
• Cohen, Myron S
• Hurt, Christopher B
• Burwen, Dale R
• Marovich, Mary A
• Brown, Elizabeth R
• Heirman, Ingeborg
• Davis, John D
• Turner, Kenneth C
• Ramesh, Divya
• Mahmood, Adnan
• Hooper, Andrea T
• Hamilton, Jennifer D
• Kim, Yunji
• Purcell, Lisa A
• Baum, Alina
• Kyratsous, Christos A
• Krainson, James
• Perez-Perez, Richard
• Mohseni, Rizwana
• Kowal, Bari
• DiCioccio, A Thomas
• Geba, Gregory P
• Stahl, Neil
• Lipsich, Leah
• Braunstein, Ned
• Herman, Gary
• Yancopoulos, George D
• Weinreich, David M

Titel

Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial

Ist Teil von

• JAMA : the journal of the American Medical Association, 2022-02, Vol.327 (5), p.432

Ort / Verlag

United States

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Easy-to-administer anti-SARS-CoV-2 treatments may be used to prevent progression from asymptomatic infection to symptomatic disease and to reduce viral carriage. To evaluate the effect of combination subcutaneous casirivimab and imdevimab on progression from early asymptomatic SARS-CoV-2 infection to symptomatic COVID-19. Randomized, double-blind, placebo-controlled, phase 3 trial of close household contacts of a SARS-CoV-2-infected index case at 112 sites in the US, Romania, and Moldova enrolled July 13, 2020-January 28, 2021; follow-up ended March 11, 2021. Asymptomatic individuals (aged ≥12 years) were eligible if identified within 96 hours of index case positive test collection. Results from 314 individuals positive on SARS-CoV-2 reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) testing are reported. Individuals were randomized 1:1 to receive 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each; n = 158), or placebo (n = 156). The primary end point was the proportion of seronegative participants who developed symptomatic COVID-19 during the 28-day efficacy assessment period. The key secondary efficacy end points were the number of weeks of symptomatic SARS-CoV-2 infection and the number of weeks of high viral load (>4 log10 copies/mL). Among 314 randomized participants (mean age, 41.0 years; 51.6% women), 310 (99.7%) completed the efficacy assessment period; 204 were asymptomatic and seronegative at baseline and included in the primary efficacy analysis. Subcutaneous casirivimab and imdevimab, 1200 mg, significantly prevented progression to symptomatic disease (29/100 [29.0%] vs 44/104 [42.3%] with placebo; odds ratio, 0.54 [95% CI, 0.30-0.97]; P = .04; absolute risk difference, -13.3% [95% CI, -26.3% to -0.3%]). Casirivimab and imdevimab reduced the number of symptomatic weeks per 1000 participants (895.7 weeks vs 1637.4 weeks with placebo; P = .03), an approximately 5.6-day reduction in symptom duration per symptomatic participant. Treatment with casirivimab and imdevimab also reduced the number of high viral load weeks per 1000 participants (489.8 weeks vs 811.9 weeks with placebo; P = .001). The proportion of participants receiving casirivimab and imdevimab who had 1 or more treatment-emergent adverse event was 33.5% vs 48.1% for placebo, including events related (25.8% vs 39.7%) or not related (11.0% vs 16.0%) to COVID-19. Among asymptomatic SARS-CoV-2 RT-qPCR-positive individuals living with an infected household contact, treatment with subcutaneous casirivimab and imdevimab antibody combination vs placebo significantly reduced the incidence of symptomatic COVID-19 over 28 days. ClinicalTrials.gov Identifier: NCT04452318.